Literature DB >> 15309527

Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.

Georg Lenz1, Grit Hutter, Wolfgang Hiddemann, Martin Dreyling.   

Abstract

Gene silencing of DNA repair genes hMLH1 and MGMT caused by aberrant promoter methylation has been detected in various solid tumors. However, in acute myeloid leukemia (AML) the frequency of hMLH1 and MGMT promoter methylation is not yet fully elucidated. To determine the methylation status and expression of hMLH1 and MGMT, we investigated 22 AML cases by methylation-specific polymerase chain reaction (MS-PCR) and reverse transcription PCR (RT-PCR). To exclude unspecific PCR amplifications DNA sequencing was performed. hMLH1 promoter methylation was detectable in 4 of 20 AML cases. However, DNA sequencing could only confirm a methylated hMLH1 promoter in one case. mRNA expression was absent in one case and reduced in another. However, these cases did not display aberrant promoter methylation. In contrast, MGMT promoter methylation was not detectable in the investigated AML patient samples. Accordingly, MGMT mRNA expression was found to be normal in all but one case. Aberrant promoter methylation of hMLH1 was detectable only in a small number of AML cases. Additionally, in two cases the promoter methylation detected by MS-PCR could not be confirmed by sequencing, clearly indicating the importance of controlling MS-PCR results by the more specific sequence analysis. Surprisingly, hMLH1 promoter methylation was not associated with gene silencing, suggesting monoallelic methylation or promoter methylation only in a small subpopulation of malignant cells. The reduced mRNA expression in additional samples may indicate an involvement of hMLH1 in the malignant transformation in a small subset of cases. In contrast, MGMT does not seem to be involved in the pathogenesis of AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309527     DOI: 10.1007/s00277-004-0925-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells.

Authors:  Nada Kraguljac Kurtović; Milena Krajnović; Andrija Bogdanović; Nada Suvajdžić; Jelica Jovanović; Bogomir Dimitrijević; Milica Colović; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-07-07       Impact factor: 3.064

2.  Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.

Authors:  Elizabeth A Griffiths; Steven D Gore; Craig M Hooker; Helai P Mohammad; Michael A McDevitt; B Douglas Smith; Judith E Karp; James G Herman; Hetty E Carraway
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

Review 3.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  DNA methyltransferases, DNA damage repair, and cancer.

Authors:  Bilian Jin; Keith D Robertson
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma.

Authors:  Abdel-Rahman N Zekri; Abeer A Bahnasy; Fatma Elzahraa M Shoeab; Waleed S Mohamed; Dina H El-Dahshan; Fahmey T Ali; Gilane M Sabry; Nairajana Dasgupta; Sayed S Daoud
Journal:  J Adv Res       Date:  2013-01-26       Impact factor: 10.479

6.  Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.

Authors:  Xing Wu; Fenlang Wu; Dongwen Xu; Tao Zhang
Journal:  J Neurooncol       Date:  2016-01-12       Impact factor: 4.130

7.  MGMT promoter methylation as a potential prognostic marker for acute leukemia.

Authors:  Dominika Sobieszkoda; Joanna Czech; Natalia Gablo; Marta Kopanska; Jacek Tabarkiewicz; Agnieszka Kolacinska; Tadeusz Robak; Izabela Zawlik
Journal:  Arch Med Sci       Date:  2017-10-31       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.